CYP2C19 and epilepsy: Therefore, it is recommended that when VPA is used in the treatment of epilepsy, the dosage should be increased for patients with CYP2C19*3 GG genotype showing fast metabolism, while the dosage be appropriately reduced for patients with CYP2C19*3 AA genotype.